Search bioRxiv⌕ Search

Biology subjects

Kikani, R.

Publications and source records attributed to Kikani, R..

2 recordsLinked to original sources

Engineered nanosponges mitigate peripheral stress-induced neuroinflammation and restore cognitive function

Systemic inflammation is increasingly recognized as a key driver of neuroinflammation and cognitive dysfunction, particularly in the aging population. Yet, therapeutic interventions that broadly attenuate circulating inflammatory mediators without suppressing host immunity remain limited. Here, we report the development of taurine functionalized hyaluronic acid nanosponges (HA Tau) that blunt systemic inflammatory cascades to protect against downstream neurocognitive impairment. Using molecular docking calculations and experimental validations, we show that taurine functionalization enhances multivalent interactions with diverse cytokines, enabling broad-spectrum sequestration of inflammatory proteins from both murine and human plasma while preserving the intrinsic hypochlorous acid neutralizing ability of taurine. In aged mice undergoing orthopedic surgery, systemic administration of HA Tau nanosponges lowered the levels of circulating inflammatory mediators, preserved blood brain barrier integrity, and attenuated glial cell activation. These effects were accompanied by improved hippocampal neuronal activity and spatial working memory in mice. By dampening peripheral inflammatory surges, the nanosponges limit peripheral-to-central inflammatory signaling without directly targeting the central nervous system. Collectively, these findings demonstrate systemic inflammatory modulation could be an effective strategy for mitigating peripheral insult-induced neuroinflammation and cognitive decline, and position HA Tau nanosponges as a versatile biomaterial platform for treating inflammation-driven disorders.

bioengineering↗

Patient-Specific Vascularized Lung Tumor Organoids for Tumor-Immune Profiling

The use of cellular systems to advance cancer therapeutics has expanded rapidly, spanning cell therapies to patient-specific tumor models. Platforms that recapitulate key features of the tumor microenvironment, including vascular and immune components, hold significant potential to improve the predictive power and translational relevance of preclinical models. Here, we report a vascularized tumor organoid platform that combines self-organizing microvascular networks with patient-derived tumor organoids and tumor-infiltrating lymphocytes. To minimize non-specific endothelial immunogenicity and enable broader compatibility across patient samples, we engineered the vasculature using {beta}2-microglobulin-knockout endothelial cells. Leveraging this system, we established patient-specific, lymphocyte-incorporated tumor models that enabled quantitative assessment of T cell infiltration. In conjunction with immune checkpoint blockade, this platform distinguishes responder and non-responder patient samples, consistent with the clinical observations. Single-cell RNA-sequencing revealed tumor-intrinsic and immune-associated programs underlying this stratification, identifying tumor-driven hyperangiogenic signaling as a barrier to T cell extravasation. Pharmacological co-targeting of PD1 and VEGF restored T cell infiltration in non-responder organoids, shifting them from an immune-excluded to an immune-inflamed state. Together, this vascularized tumor organoid platform provides a predictive and mechanistic framework for modeling patient-specific immunotherapy responses and design of combination therapies.

bioengineering↗